Get the Stockscreener App
0.00
100.00%
-8.68
After Hours:
8.69
8.69
+
Sage Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$8.68
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$544.94M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
0.00
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.36
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 544.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Resumed | BofA Securities | Underperform |
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Postpartum Depression Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers - Barchart.com
How Sage Therapeutics Inc. stock compares to industry benchmarksInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock enhance shareholder valueJuly 2025 Review & Technical Pattern Alert System - Newser
How big funds are accumulating Sage Therapeutics Inc. (SG7) stockStop Loss & Precise Swing Trade Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock outperform small cap peersDip Buying & Long-Term Safe Investment Ideas - Newser
Why Sage Therapeutics Inc. stock remains a top recommendationJuly 2025 Closing Moves & Safe Entry Zone Tips - Newser
How Sage Therapeutics Inc. (SG7) stock benefits from digital adoptionJuly 2025 Selloffs & Breakout Confirmation Trade Signals - Newser
What is the fair value of Sage Therapeutics Inc. stock now2025 Momentum Check & Consistent Profit Trading Strategies - Newser
Is Sage Therapeutics Inc. stock a buy on dips2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - BỘ NỘI VỤ
What analysts say about Sage Therapeutics Inc stockInsider Trading Compliance & High Return Wealth Building - earlytimes.in
Is Sage Therapeutics Inc. (SG7) stock undervalued after correctionWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What technical patterns form on Sage Therapeutics Inc. (SG7) stock chartsRate Cut & Weekly Market Pulse Updates - newser.com
How Sage Therapeutics Inc. stock benefits from global expansionJuly 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
Can Sage Therapeutics Inc. (SG7) stock resist broad market declines2025 Trading Recap & AI Forecast for Swing Trade Picks - newser.com
Is Sage Therapeutics Inc. (SG7) stock a buy during volatile marketsTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Can Sage Therapeutics Inc. (SG7) stock sustain revenue momentumWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Sage Therapeutics Inc. stock momentum explainedJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
Sage Therapeutics Inc. stock prediction for this weekWeekly Trade Summary & Consistent Profit Focused Trading Strategies - newser.com
Will Sage Therapeutics Inc. benefit from macro trends2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Will Sage Therapeutics Inc. (SG7) stock beat value stocks2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Why Sage Therapeutics Inc. (SG7) stock stays on top picks2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
How Sage Therapeutics Inc. stock compares to growth peers2025 Technical Patterns & Growth Focused Stock Pick Reports - newser.com
Will Sage Therapeutics Inc. stock recover after recent dropWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Published on: 2025-11-16 05:15:30 - newser.com
Sage Therapeutics Inc SG7 Stock Analysis and ForecastEarnings Revision Updates & Free Stock Trading Workshops - earlytimes.in
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):